Overview
NICE is unable to make a recommendation on olaparib (Lynparza) for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy. This is because AstraZeneca did not provide an evidence submission.
Last reviewed: 8 December 2021
Next review: We will review this decision if the company decides to make a submission.